[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"r-chop-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:r-chop-chemotherapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100650276","phase-2-pirtobrutinib--r-chop-for-untreated-non-gcb-dlbcl-100650276",false,"NCT07744737","Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL","A Prospective, Multicenter Clinical Study of Pirtobrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) for the Treatment of Previously Untreated Non-GCB DLBCL","Inclusion Criteria:\n\n1. Histopathologically confirmed non-GCB diffuse large B-cell lymphoma (DLBCL) (per the 2016 WHO diagnostic criteria);\n2. Whole-body PET\u002FCT performed within 28 days prior to study enrollment demonstrating at least one measurable lesion (per the 2014 Lugano Criteria);\n3. Age 18-80 years, with estimated survival \\> 3 months;\n4. No prior anti-lymphoma treatment;\n5. Able to provide written informed consent and comply with scheduled study visits and required procedures specified in the protocol;\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n7. Adequate organ and bone marrow function, defined as follows: Hematology: Absolute neutrophil count (ANC) ≥ 0.5 × 10⁹\u002FL; platelet count (PLT) ≥ 50 × 10⁹\u002FL; hemoglobin (HGB) ≥ 8.0 g\u002FdL. No administration of granulocyte growth factors, platelet transfusions or red blood cell transfusions within 7 days before testing. Liver function: Total serum bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 50 mL\u002Fmin. Cardiac function: New York Heart Association (NYHA) functional class \\\u003C III; left ventricular ejection fraction (LVEF) ≥ 50% on echocardiography. Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; activated partial thromboplastin time (APTT) ≤ upper limit of normal +10 s; prothrombin time (PT) ≤ upper limit of normal +3 s. Thyroid function: Baseline thyroid-stimulating hormone (TSH) within normal range, or abnormal baseline TSH with normal T3\u002FT4 and absence of related clinical symptoms.\n8. Female subjects of childbearing potential, or male subjects whose sexual partners are females of childbearing potential, must adopt effective contraceptive measures throughout the treatment period and for 90 days after the last treatment administration.\n\nExclusion Criteria:\n\n1. Central nervous system involvement;\n2. History of hypersensitivity to the study drug, similar agents, or excipients;\n3. Concurrent other malignancies requiring treatment or intervention;\n4. Major surgical procedure performed within 4 weeks prior to treatment (excluding vascular access catheterization or biopsy);\n5. Any life-threatening disease, medical condition, or organ dysfunction that, in the Investigator's opinion, may compromise patient safety or adherence to study procedures;\n6. Poorly controlled cardiac symptoms or diseases, including: i. Heart failure of NYHA Class ≥ II; ii. Unstable angina pectoris; iii. Myocardial infarction within the past 12 months; iv. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n7. Patients with active bleeding;\n8. Uncontrolled active systemic bacterial, viral, fungal or parasitic infection (excluding fungal nail infection), or other clinically significant active disease process that renders the patient unsuitable for participation in this trial as judged by the Investigator.\n9. Known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome (AIDS).\n10. Patients with active chronic hepatitis B or active hepatitis C are excluded.Patients positive for hepatitis B surface antigen, hepatitis B core antibody or hepatitis C virus antibody during screening must undergo further testing for HBV-DNA and HCV-RNA. Patients with stable hepatitis B after antiviral therapy (HBV-DNA \\\u003C 2500 copies\u002FmL or 500 IU\u002FmL) and cured hepatitis C patients (HCV-RNA below the lower limit of detection) are eligible for enrollment.\n11. Confirmed prior history of neurological or psychiatric disorders, including epilepsy or dementia;\n12. Pregnant or lactating women;\n13. Received any other investigational product within 1 month prior to the first dose;\n14. Other conditions that, in the Investigator's judgment, may interfere with the evaluation of efficacy or safety of the study treatment.","ALL","18 Years","80 Years",{"count":20,"type":21},34,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To evaluate the efficacy and safety of pirtobrutinib combined with R-CHOP in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL)",[27,28,29],"DLBCL - Diffuse Large B Cell Lymphoma","R-CHOP Chemotherapy","Pirtobrutinib","NOT_YET_RECRUITING","2026-08-04",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":21},"2026-07-30",{"date":38,"type":21},"2029-04-30",{"name":40,"class":41},"Changzhou No.2 People's Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100584577","phase-2-chidamide-plus-r-chop-in-newly-diagnosed-double-expressor-diffuse-large-b-cell-lymphoma-with-other-molecular-subtypes-100584577","NCT06891157","Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes","Chidamide Plus R-CHOP (CR-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes: A Prospective, Multicenter Phase II Trial","Inclusion Criteria:\n\n* Patients must meet all of the following inclusion criteria to be eligible for enrollment:\n\n  1. ≥18 years of age;\n  2. Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;\n  3. Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the \"Other\" subtype;\n  4. Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;\n  5. Measurable lesions identified on cross-sectional imaging through diagnostic modalities (computed tomography \\[CT\\] or magnetic resonance imaging \\[MRI\\]) are defined as the presence of at least one two-dimensional lesion with a maximum cross-sectional diameter (GTD) ≥1.5 cm, irrespective of the short-axis diameter;\n  6. The Eastern Cooperative Oncology Group (ECOG) performance status score is ≤2；\n  7. Adequate hepatic function is defined as: total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN; alkaline phosphatase (ALP) ≤ 5 × ULN; serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 35 mL\u002Fmin as calculated by the Cockcroft-Gault formula;\n  8. Voluntary participation with willingness to provide the aforementioned treatment data, accompanied by a signed and dated informed consent form.\n\n     Exclusion Criteria:\n* Patients who meet any of the following criteria will be excluded from the study：\n\n  1. Currently enrolled in another clinical trial；\n  2. Received prior lymphoma treatment with alternative regimens before enrollment;\n  3. Presence of concurrent malignant tumors;\n  4. Deemed ineligible for participation by the investigator's judgment；\n  5. Presence of severe psychiatric or neurological disorders that may impair the ability to provide informed consent and\u002For affect the reporting or observation of adverse events；\n  6. Patients unable to comply with follow-up requirements；\n  7. Pregnant or lactating women, and patients of childbearing potential unwilling to use contraception;\n  8. Active infection or uncontrolled HBV (HBsAg positive and\u002For HBcAb positive and HBV DNA positive), HCV positive",{"count":51,"type":21},148,[24],"Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes",[55,28,27,56],"Chidamide","Double-expressor Lymphoma (DEL)","RECRUITING","2025-03-20",{"date":60,"type":34},"2025-03-24",{"date":62,"type":34},"2024-08-20",{"date":64,"type":21},"2027-08-20",{"name":66,"class":41},"The First Affiliated Hospital with Nanjing Medical University"]